Communiqué de presse Archives

Novigenix nomme Jan Groen au poste de CEO pour conduire la transition de la société vers une plateforme technologique de diagnostic du cancer et de médecine de précision

Par Novigenix|2019-05-13T13:37:47+02:0013 mai 2019|News Novigenix|

La plateforme ImmunoTranscriptomic combine l'identification des signatures d'ARNm de cellules immunitaires avec l'IA pour la détection précoce du cancer LAUSANNE, SUISSE - 7h00, CET, 13 mai 2019 - Novigenix SA, une société pionnière en ImmunoTranscriptomics qui développe et commercialise des produits pour la détection précoce du cancer et la médecine de précision a annoncé

Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox®, its blood based colorectal cancer test

Par Novigenix|2018-03-19T11:43:14+02:0015 mars 2017|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse|

Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold

Novigenix publishes multi-center study of Colox® in Clinical Cancer Research

Par Novigenix|2018-03-09T12:06:37+02:009 mai 2016|Non classé|

Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with

Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer

Par Sebastien|2018-03-09T14:12:44+02:0012 février 2015|Non classé|

LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox